Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia

Inclusion Criteria: * Men and non-pregnant/lactating women between the ages of 18 and 45. * Body Mass Index (BMI) ≥18 and ≤30 * Participants who are able to give written informed consent and willing to comply with all study-related procedures. Exclusion Criteria: * Known clinically manifest atherosclerotic cardiovascular disease, including coronary disease, cerebrovascular disease, or peripheral vascular disease * History of diabetes mellitus * Fasting glucose \>126mg/dL at screening * History of a non-skin malignancy within the previous 5 years * Renal insufficiency as defined by creatinine outside of lab defined normal range or eGFR \<60 ml/Kg/min at Screening Visit * History of liver disease or abnormal Liver Function Tests (LFTs) (aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phosphatase, gamma-glutamyl transpeptidase (GGT) \> 1.5x upper limit of normal (ULN); bilirubin \> 2x ULN) at Screening Visit * Men who are unwilling to limit alcohol consumption to \< 14 alcoholic drinks per week or \< 4 alcoholic drinks per occasion (American Medical Association/National Institute on Alcohol Abuse and Alcoholism (AMA / NIAAA) criteria for "at risk" usage levels) while participating in the study * Women who are unwilling to limit alcohol consumption to \< 7 alcoholic drinks per week or \< 3 alcoholic drinks per occasion (AMA / NIAAA criteria for "at risk" usage levels) while participating in the study * Total white blood cell count less than or equal to 3.0 THO/uL * Hemoglobin less than 11.0 g/dL * Any major active rheumatologic, pulmonary, or dermatologic disease or inflammatory condition or minor active infection * Self-reported history of HIV positive * First degree family history of premature cardiovascular disease event (father or brother if diagnosed at before 55 years of age; mother or sister if diagnosed before 65 years of age) * Patients who have undergone any organ transplant * Individuals who currently use tobacco products or have done so in the previous 30 days * Treatment with aspirin, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), cyclooxygenase-2 (COX-2) inhibitors, steroids or any immunomodulatory therapy 2 weeks prior to the Screening Visit * Treatment with statins, fibrates or niacin 4 weeks prior to the Screening Visit. * Current daily use of Vitamin C \> 1000 mg, Beta carotene \> 1000 IU, vitamin A \> 5000 IU, vitamin E \> 400 IU, and selenium \> 200 mcg * Participants who are unwilling to eliminate omega-3 fatty acid (eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA)) supplements and/or fortified food, or have their usual intake of high omega-3 fish (tuna and other non-fried fish) be \> 3 to 4 servings per month as assessed by a simple screening questionnaire * Positive urine pregnancy test result. * Participation in another clinical trial within the previous 6 weeks prior to the Screening Visit. * Poorly controlled blood pressure (BP \> 160/110) or on any anti-hypertensive medications. * A diagnosis of metabolic syndrome using updated 2004 National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII) criteria. * Any medical condition or abnormal laboratory value that is judged clinically significant by an investigator